Jazz Pharmaceuticals Plc (JAZZ)

$131.03

-0.2

(-0.15%)▲

Market is closed - opens 7 PM, 29 Sep 2023

Insights on Jazz Pharmaceuticals Plc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 892.81M → 957.31M (in $), with an average increase of 6.7% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -240.72M → 104.43M (in $), with an average increase of 240.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 84.6% return, outperforming this stock by 82.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 165.1% return, outperforming this stock by 172.4%

Performance

  • $130.87
    $132.42
    $131.03
    downward going graph

    0.12%

    Downside

    Day's Volatility :1.17%

    Upside

    1.05%

    downward going graph
  • $120.64
    $160.96
    $131.03
    downward going graph

    7.93%

    Downside

    52 Weeks Volatility :25.05%

    Upside

    18.59%

    downward going graph

Returns

PeriodJazz Pharmaceuticals PlcSector (Health Care)Index (Russel 2000)
3 Months
7.13%
-1.1%
0.0%
6 Months
-7.97%
1.6%
0.9%
1 Year
1.78%
4.2%
3.1%
3 Years
-7.25%
24.2%
17.1%

Highlights

Market Capitalization
8.4B
Book Value
$55.61
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.61
PEG Ratio
3.99
Wall Street Target Price
201.06
Profit Margin
-2.3%
Operating Margin TTM
26.8%
Return On Assets TTM
5.61%
Return On Equity TTM
-2.57%
Revenue TTM
3.8B
Revenue Per Share TTM
59.41
Quarterly Revenue Growth YOY
2.6%
Gross Profit TTM
3.4B
EBITDA
1.6B
Diluted Eps TTM
-1.61
Quarterly Earnings Growth YOY
1.76
EPS Estimate Current Year
18.59
EPS Estimate Next Year
20.17
EPS Estimate Current Quarter
4.43
EPS Estimate Next Quarter
4.56

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 21 Wall street analysts offering stock ratings for Jazz Pharmaceuticals Plc(by analysts ranked 0 to 5 stars)
Based on 21 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
18
21
21
Hold
3
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 53.45%

Current $131.03
Target $201.06

Company Financials

FY17Y/Y Change
Revenue
1.6B
↑ 8.79%
Net Income
487.8M
↑ 22.94%
Net Profit Margin
30.14%
↑ 3.47%
FY18Y/Y Change
Revenue
1.9B
↑ 16.82%
Net Income
447.1M
↓ 8.35%
Net Profit Margin
23.64%
↓ 6.5%
FY19Y/Y Change
Revenue
2.2B
↑ 14.32%
Net Income
523.4M
↑ 17.06%
Net Profit Margin
24.21%
↑ 0.57%
FY20Y/Y Change
Revenue
2.4B
↑ 9.34%
Net Income
238.6M
↓ 54.41%
Net Profit Margin
10.1%
↓ 14.11%
FY21Y/Y Change
Revenue
3.1B
↑ 30.91%
Net Income
-329.7M
↓ 238.16%
Net Profit Margin
-10.65%
↓ 20.75%
FY22Y/Y Change
Revenue
3.7B
↑ 18.26%
Net Income
-531.4M
↑ 61.2%
Net Profit Margin
-14.52%
↓ 3.87%
Q1 FY22Q/Q Change
Revenue
813.7M
↓ 9.26%
Net Income
1.6M
↓ 104.66%
Net Profit Margin
0.2%
↑ 4.14%
Q2 FY22Q/Q Change
Revenue
932.9M
↑ 14.64%
Net Income
34.7M
↑ 2004.74%
Net Profit Margin
3.72%
↑ 3.52%
Q3 FY22Q/Q Change
Revenue
940.7M
↑ 0.83%
Net Income
-19.6M
↓ 156.68%
Net Profit Margin
-2.09%
↓ 5.81%
Q4 FY22Q/Q Change
Revenue
972.1M
↑ 3.35%
Net Income
-240.7M
↑ 1125.18%
Net Profit Margin
-24.76%
↓ 22.67%
Q1 FY23Q/Q Change
Revenue
892.8M
↓ 8.16%
Net Income
69.4M
↓ 128.84%
Net Profit Margin
7.78%
↑ 32.54%
Q2 FY23Q/Q Change
Revenue
957.3M
↑ 7.22%
Net Income
104.4M
↑ 50.44%
Net Profit Margin
10.91%
↑ 3.13%
FY17Y/Y Change
Total Assets
5.1B
↑ 6.74%
Total Liabilities
2.4B
↓ 17.53%
FY18Y/Y Change
Total Assets
5.2B
↑ 1.56%
Total Liabilities
2.4B
↑ 1.47%
FY19Y/Y Change
Total Assets
5.5B
↑ 6.45%
Total Liabilities
2.4B
↓ 0.74%
FY20Y/Y Change
Total Assets
6.5B
↑ 18.0%
Total Liabilities
2.9B
↑ 18.46%
FY21Y/Y Change
Total Assets
12.3B
↑ 88.17%
Total Liabilities
8.3B
↑ 189.74%
FY22Y/Y Change
Total Assets
10.8B
↓ 11.9%
Total Liabilities
7.7B
↓ 7.01%
Q1 FY22Q/Q Change
Total Assets
11.8B
↓ 4.31%
Total Liabilities
8.2B
↓ 2.08%
Q2 FY22Q/Q Change
Total Assets
11.2B
↓ 4.83%
Total Liabilities
8.0B
↓ 1.97%
Q3 FY22Q/Q Change
Total Assets
10.4B
↓ 7.28%
Total Liabilities
7.6B
↓ 4.5%
Q4 FY22Q/Q Change
Total Assets
10.8B
↑ 4.34%
Total Liabilities
7.7B
↑ 1.44%
Q1 FY23Q/Q Change
Total Assets
11.0B
↑ 1.96%
Total Liabilities
7.6B
↓ 1.41%
Q2 FY23Q/Q Change
Total Assets
11.3B
↑ 1.93%
Total Liabilities
7.7B
↑ 1.24%
FY17Y/Y Change
Operating Cash Flow
693.1M
↑ 17.37%
Investing Cash Flow
-269.0M
↓ 84.63%
Financing Cash Flow
-409.1M
↓ 175.62%
FY18Y/Y Change
Operating Cash Flow
798.9M
↑ 15.27%
Investing Cash Flow
-394.5M
↑ 46.68%
Financing Cash Flow
-479.1M
↑ 17.11%
FY19Y/Y Change
Operating Cash Flow
776.4M
↓ 2.82%
Investing Cash Flow
-155.3M
↓ 60.63%
Financing Cash Flow
-293.7M
↓ 38.69%
FY20Y/Y Change
Operating Cash Flow
899.6M
↑ 15.87%
Investing Cash Flow
-1.0B
↑ 548.85%
Financing Cash Flow
528.1M
↓ 279.77%
FY21Y/Y Change
Operating Cash Flow
778.5M
↓ 13.47%
Investing Cash Flow
-5.2B
↑ 417.25%
Financing Cash Flow
4.0B
↑ 651.89%
FY22Y/Y Change
Operating Cash Flow
1.3B
↑ 63.39%
Investing Cash Flow
-446.2M
↓ 91.44%
Financing Cash Flow
-529.5M
↓ 113.34%
Q1 FY22Q/Q Change
Operating Cash Flow
209.0M
↑ 17.57%
Investing Cash Flow
-37.3M
↑ 269.52%
Financing Cash Flow
-270.8M
↑ 9.81%
Q2 FY22Q/Q Change
Operating Cash Flow
303.0M
↑ 45.01%
Investing Cash Flow
-89.2M
↑ 139.09%
Financing Cash Flow
10.8M
↓ 103.98%
Q3 FY22Q/Q Change
Operating Cash Flow
418.0M
↑ 37.93%
Investing Cash Flow
4.6M
↓ 105.16%
Financing Cash Flow
-289.1M
↓ 2782.13%
Q4 FY22Q/Q Change
Operating Cash Flow
342.0M
↓ 18.19%
Investing Cash Flow
-324.4M
↓ 7148.63%
Financing Cash Flow
19.6M
↓ 106.78%
Q1 FY23Q/Q Change
Operating Cash Flow
320.7M
↓ 6.22%
Investing Cash Flow
-4.8M
↓ 98.51%
Financing Cash Flow
-29.8M
↓ 252.01%
Q2 FY23Q/Q Change
Operating Cash Flow
296.8M
↓ 7.47%
Investing Cash Flow
-85.7M
↑ 1678.08%
Financing Cash Flow
-96.7M
↑ 224.52%

Technicals Summary

Sell

Neutral

Buy

Jazz Pharmaceuticals Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc
-7.65%
-7.97%
1.78%
-7.25%
-21.95%
Moderna, Inc.
Moderna, Inc.
-12.64%
-32.32%
-18.59%
40.95%
434.62%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.2%
0.68%
18.02%
45.57%
106.06%
Novo Nordisk A/s
Novo Nordisk A/s
-2.18%
18.08%
84.58%
165.14%
289.05%
Seagen, Inc.
Seagen, Inc.
3.05%
4.69%
54.33%
11.57%
175.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.55%
11.62%
19.58%
30.6%
81.41%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc
NA
NA
3.99
18.59
-0.03
0.06
0.0
55.61
Moderna, Inc.
Moderna, Inc.
34.67
34.67
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
21.73
21.73
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.3
43.3
2.03
1.65
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.52
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.94
26.94
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Jazz Pharmaceuticals Plc
Jazz Pharmaceuticals Plc
Buy
$8.4B
-21.95%
NA
-2.3%
Moderna, Inc.
Moderna, Inc.
Buy
$37.3B
434.62%
34.67
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.4B
106.06%
21.73
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$410.6B
289.05%
43.3
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$40.6B
175.61%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.2B
81.41%
26.94
35.4%

Institutional Holdings

  • BlackRock Inc

    10.90%

  • Vanguard Group Inc

    10.06%

  • State Street Corporation

    3.76%

  • LSV Asset Management

    3.67%

  • Wellington Management Company LLP

    2.96%

  • JPMorgan Chase & Co

    2.69%

Corporate Announcements

  • Jazz Pharmaceuticals Plc Earnings

    Jazz Pharmaceuticals Plc’s price-to-earnings ratio stands at None

    Read More

Company Information

jazz pharmaceuticals plc (nasdaq: jazz) is an international biopharmaceutical company focused on improving patients’ lives by identifying, developing and commercializing meaningful products that address unmet medical needs. we are a diverse company of over 875 employees focused on portfolio of products and/or product candidates in the areas of sleep, hematology/oncology and pain. founded in 2003 and headquartered in dublin, ireland, jazz pharmaceuticals has u.s. offices in palo alto, ca and philadelphia, pa, and has offices in various other locations in europe. the company’s maintains a highly collaborative and entrepreneurial culture where employees focus on how they accomplish success as well as what is done to accomplish results by operating in accordance with the company’s core values: integrity, collaboration, passion, innovation and the pursuit of excellence. we plan to build upon our portfolio of products through acquisition and/or in-licensing activities, and leveraging our uni

Organization
Jazz Pharmaceuticals Plc
Employees
2800
CEO
Mr. Bruce C. Cozadd
Industry
Health Technology

Discover More

FAQs